WHOOP is First Wearable to Be Used in Phase 3 COVID-19 Vaccine Trials
August 13, 2020 | PR NewswireEstimated reading time: 2 minutes
Abu Dhabi-based G42 Healthcare has announced a volunteer healthcare management program with Boston-based wearable technology firm WHOOP. The partnership will offer volunteers participating in the world's first Phase III trials of an inactivated COVID-19 vaccine the opportunity to benefit from a 24/7 fitness and health monitor to measure key biometrics. This is the first trial of its kind to feature wearable technology and will include thousands of volunteers who are participating in the trials.
The Whoop4Humanity initiative ensures that volunteers who now join the clinical trials at ADNEC in Abu Dhabi and the Al Qarain Center in Sharjah, including those coming in for the second dose, can further enhance their participation in the trails by using the new wearable devices which will enable them to check their daily heart rate, respiratory rate, heart rate variability, sleep performance, and more.
Commenting on the new partnership, G42 Healthcare CEO Ashish Koshy said: "As a digital business, this new partnership is a logical extension of the highly-advanced AI and super computer solutions we are already using in the trials process. New volunteers will be invited to engage with the technology developed by WHOOP to enhance their individual volunteer experience and contribute to the advanced research involved in these sophisticated trials.
"We believe that giving volunteers an opportunity to use the WHOOP Strap 3.0 wearable device will reinforce their confidence in the trial by giving them the ability to check on several daily health data points. This will complement the world-class clinical expertise that the healthcare professionals in the UAE are providing to the volunteers and ensure their safety and well-being throughout the trials process."
G42 Healthcare believes that WHOOP can be a powerful tool to boost the comprehensive volunteer healthcare management program by helping thousands of vaccine volunteers to self-monitor their well-being while measuring their fitness, sleep, and recovery levels during the trials. WHOOP provides valuable insights and actionable feedback around specific markers, thus encouraging better decision making for volunteers' health and contributing to the trials' overall success.
"WHOOP is proud to partner with G42 Healthcare and participate in their innovative Phase III COVID-19 vaccine trial," said Will Ahmed, WHOOP Founder & CEO. "The continuous biometric monitoring offered by WHOOP will help volunteers evaluate any changes to their health and help researchers vastly increase their understanding of the vaccine's impact. This partnership represents the future of healthcare: using continuous monitoring and artificial intelligence to better understand the effect of drugs, vaccines, and other treatments."
WHOOP uniquely blends hardware, software, and industry-leading accurate measurements to help people sharpen the edges of performance, create impactful behavior change and a new set of positive individual habits, and empower them to optimize all facets of life.
The trials began in Abu Dhabi on 16th July and are being managed by G4 Healthcare in partnership with the Department of Health - Abu Dhabi, the UAE Ministry of Health and Prevention (MOHAP) and Abu Dhabi Health Services Company (SEHA). They are being conducted following the international guidelines stipulated by the World Health Organization (WHO) and the United States Food & Drug Administration (USFDA).
The Phase III clinical trials follow the success of the Phase I and Phase II trials conducted by Sinopharm in China, which resulted in 100% of the volunteers generating antibodies to SARS-CoV-2, the virus that causes COVID-19, after two doses in 28 days. The Phase III trials are open to individual volunteers aged between 18 and 60 living in the UAE and Bahrain and will last for six to twelve months, with the volunteers required to be available for follow ups during this time.
Suggested Items
It’s Only Common Sense: Seeking the Possibility of Opportunity
03/11/2024 | Dan Beaulieu -- Column: It's Only Common SenseWe are often so immersed in what we are doing that we don’t have time to lift our heads and open our eyes to the possibility of opportunity. Why is this a problem? It’s because being open to opportunities is crucial for success in sales (as it is in all of business and in). Over the years, I have found there are several ways to take advantage of opportunities. The absolute best way is to always have an open mind. Here are some ways I do that.
EMA Design Automation and Hawk Ridge Systems Reshape Landscape with Full ECAD/MCAD Convergence
02/07/2024 | EMA Design AutomationEMA Design Automation and Hawk Ridge Systems entered a strategic partnership to give customers a full ECAD/MCAD design experience, leveraging best-in-class tools and support for the entire electronic product design flow.
Standard of Excellence: Selling to PCB Fabricators Now and in the Future
01/17/2024 | Anaya Vardya -- Column: Standard of ExcellenceFor the past few years, PCB fabricators have made improvements to keep up with your customers. We have bought new equipment, updated our processes, and increased our quality, technology, and performance to make sure we are providing our customers with everything they need to be successful. I thought this would be a good time to discuss and advise our vendors and suppliers on what they should do to supply us with what we need to succeed.
The Economics of Equipment Selection
01/08/2024 | Barry Matties, I-Connect007Financing capital equipment is certainly a large part of a fabricator’s economic equation. However, the selection of your equipment has a long-term economic impact, especially if you overlook a few critical points. As IPS President and CEO Mike Brask recently explained, the first step in this process is to really understand your technological needs and the flexibility that’s required for your equipment to carry you into the future.
DARPA Moves Forward on X-65 Technology Demonstrator
01/04/2024 | DARPADARPA has selected Aurora Flight Sciences to build a full-scale X-plane to demonstrate the viability of using active flow control (AFC) actuators for primary flight control. The X-65 breaks this century-old design paradigm for flight control by using jets of air from a pressurized source to shape the flow of air over the aircraft surface, with AFC effectors on several surfaces to control the plane’s roll, pitch, and yaw. Eliminating external moving parts is expected to reduce weight and complexity and to improve performance.